Early Phase 1 Fibromyalgia Trial, Recruiting NCT05068791 Sponsor: University of Alabama at Birmingham Condition: Fibromyalgia
Back to Fibromyalgia

Early Phase 1 Fibromyalgia Trial, Recruiting

NCT05068791
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman between the ages of 25 and 65
  • You have had widespread pain throughout your body for at least 12 months
  • You have been diagnosed with fibromyalgia based on the 2016 American College of Rheumatology criteria
  • You are willing and able to fill in a daily report during the early part of the study (completing at least 80% of the entries)
  • You are able to travel to UAB (University of Alabama at Birmingham) for all scheduled visits
  • You can read and write in English
  • You have never used hallucinogens, or your last use was at least 3 years ago
  • You have a trusted friend or family member who can accompany you and drive you home after the medication session
  • Your average daily pain level is at least 5 out of 10
  • If you are currently taking any medications that are not allowed in the study, you are willing to stop them for a set period of time before the study begins (confirm with trial site for details)

Who may not be able to join:

  • You are male
  • You have used opioid pain medications (such as codeine or oxycodone) in the last 60 days
  • You regularly take anti-inflammatory medications such as aspirin, ibuprofen, or naproxen
  • You take blood-thinning medications
  • You currently take certain antidepressants, mood stabilizers, antipsychotics, lithium, St. John's Wort, or other medications that affect serotonin levels (confirm with trial site for the full list)
  • You drink grapefruit juice every day
  • You have had a fever or taken antibiotics in the 4 weeks before the study starts
  • You have had surgery recently or are planning surgery during the study period
  • You are planning to move away from the Birmingham area within the next 6 months
  • You have had a vaccination recently or are planning one during the study period
  • You are currently taking part in another treatment trial
  • You are pregnant, planning to become pregnant within 6 months, or currently breastfeeding
  • You have a significant untreated or unstable mental health condition, or you scored highly on a depression screening questionnaire (confirm with trial site)
  • You have a current or past history of any psychotic disorder (such as schizophrenia)
  • You have a current or past history of bipolar disorder (type I or II)
  • A parent, sibling, or child of yours has had a psychotic disorder or bipolar disorder
  • You are currently having thoughts of harming yourself or others
  • You have been diagnosed with a rheumatological or autoimmune condition (such as lupus or rheumatoid arthritis)
  • You have a blood or clotting disorder
  • You have high blood pressure or a resting heart rate above 90 beats per minute
  • You currently have an active infection with a fever
  • Certain blood test results are outside acceptable ranges, including markers of inflammation, thyroid levels, or signs of autoimmune activity (confirm with trial site)
  • You are dependent on any mind-altering substances other than nicotine or caffeine
  • You take the antiviral medication efavirenz
  • You take certain medications used for erectile dysfunction or related conditions (confirm with trial site)
  • You have severe anaemia
  • You have certain health conditions including phenylketonuria, chronic bronchitis, emphysema, asthma, diabetes, liver disease, or a persistent cough with mucus or breathing difficulties
  • You use any medication containing dextromethorphan (found in some cough medicines)
  • Your pain is primarily caused by a condition other than fibromyalgia
  • You take certain medications that affect how the body processes drugs (known as CYP2D6 inhibitors, confirm with trial site)
  • Based on genetic testing, your body processes a certain enzyme (CYP2D6) more slowly than average (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 205-202-1387

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in daily self-reported pain severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov